Literature DB >> 33504438

The Melanocyte Lineage Factor miR-211 Promotes BRAFV600E Inhibitor Resistance.

Stephen M Ostrowski1, David E Fisher2.   

Abstract

Resistance to targeted therapy and immunotherapy remains a major obstacle in improving care for patients with advanced melanoma. MicroRNAs play important roles in regulating gene networks involved in disease progression and resistance to therapy in cancers such as melanoma. MicroRNA miR-211 contributes to melanocyte and melanoma biology and has been implicated in targeted therapy resistance. Lee et al. (2020) report a novel mechanism by which miR-211 promotes resistance to BRAFV600E inhibitor therapy via the upregulation of the extracellular signal-regulated kinase 5 signaling pathway.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33504438      PMCID： PMC7850168          DOI： 10.1016/j.jid.2020.07.010

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


  10 in total

1.  miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma.

Authors:  Marta Díaz-Martínez; Lucía Benito-Jardón; Lola Alonso; Lisa Koetz-Ploch; Eva Hernando; Joaquin Teixidó
Journal:  Cancer Res       Date:  2017-12-11       Impact factor: 12.701

2.  MicroRNA 211 Functions as a Metabolic Switch in Human Melanoma Cells.

Authors:  Joseph Mazar; Feng Qi; Bongyong Lee; John Marchica; Subramaniam Govindarajan; John Shelley; Jian-Liang Li; Animesh Ray; Ranjan J Perera
Journal:  Mol Cell Biol       Date:  2016-01-19       Impact factor: 4.272

3.  BRAFV600 inhibition alters the microRNA cargo in the vesicular secretome of malignant melanoma cells.

Authors:  Taral R Lunavat; Lesley Cheng; Berglind O Einarsdottir; Roger Olofsson Bagge; Somsundar Veppil Muralidharan; Robyn A Sharples; Cecilia Lässer; Yong Song Gho; Andrew F Hill; Jonas A Nilsson; Jan Lötvall
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-06       Impact factor: 11.205

4.  Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma.

Authors:  Carmit Levy; Mehdi Khaled; Dimitrios Iliopoulos; Maja M Janas; Steffen Schubert; Sophie Pinner; Po-Hao Chen; Shuqiang Li; Anne L Fletcher; Satoru Yokoyama; Kenneth L Scott; Levi A Garraway; Jun S Song; Scott R Granter; Shannon J Turley; David E Fisher; Carl D Novina
Journal:  Mol Cell       Date:  2010-11-25       Impact factor: 17.970

5.  The regulation of miRNA-211 expression and its role in melanoma cell invasiveness.

Authors:  Joseph Mazar; Katherine DeYoung; Divya Khaitan; Edward Meister; Alvin Almodovar; James Goydos; Animesh Ray; Ranjan J Perera
Journal:  PLoS One       Date:  2010-11-01       Impact factor: 3.240

6.  Resistance to MAPK Inhibitors in Melanoma Involves Activation of the IGF1R-MEK5-Erk5 Pathway.

Authors:  Lucía Benito-Jardón; Marta Díaz-Martínez; Nohemi Arellano-Sánchez; Paloma Vaquero-Morales; Azucena Esparís-Ogando; Joaquin Teixidó
Journal:  Cancer Res       Date:  2019-03-04       Impact factor: 12.701

7.  Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.

Authors:  Julia Boshuizen; Louise A Koopman; Oscar Krijgsman; Aida Shahrabi; Elke Gresnigt- van den Heuvel; Maarten A Ligtenberg; David W Vredevoogd; Kristel Kemper; Thomas Kuilman; Ji-Ying Song; Nora Pencheva; Jens Thing Mortensen; Marnix Geukes Foppen; Elisa A Rozeman; Christian U Blank; Maarten L Janmaat; David Satijn; Esther C W Breij; Daniel S Peeper; Paul W H I Parren
Journal:  Nat Med       Date:  2018-01-15       Impact factor: 53.440

8.  Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways.

Authors:  Christian Adam; Lorenza Fusi; Neele Weiss; Simon G Goller; Katharina Meder; Verena G Frings; Hermann Kneitz; Matthias Goebeler; Roland Houben; David Schrama; Marc Schmidt
Journal:  J Invest Dermatol       Date:  2020-05-04       Impact factor: 8.551

9.  MicroRNA-211 Modulates the DUSP6-ERK5 Signaling Axis to Promote BRAFV600E-Driven Melanoma Growth In Vivo and BRAF/MEK Inhibitor Resistance.

Authors:  Bongyong Lee; Anupama Sahoo; Junko Sawada; John Marchica; Sanjay Sahoo; Fabiana I A L Layng; Darren Finlay; Joseph Mazar; Piyush Joshi; Masanobu Komatsu; Kristiina Vuori; Petrus R de Jong; Animesh Ray; Ranjan J Perera
Journal:  J Invest Dermatol       Date:  2020-09-02       Impact factor: 8.551

Review 10.  ERK5 and Cell Proliferation: Nuclear Localization Is What Matters.

Authors:  Nestor Gomez; Tatiana Erazo; Jose M Lizcano
Journal:  Front Cell Dev Biol       Date:  2016-09-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.